PTC Therapeutics director Jacobson sells $63,369 in stock

In a recent transaction reported to the Securities and Exchange Commission, Allan Steven Jacobson, a director at PTC (NASDAQ:PTC) Therapeutics, Inc. (NASDAQ:PTCT), sold 1,230 shares of the company’s common stock. The company, currently valued at $4.1 billion, has seen its stock surge 65% over the past six months, according to InvestingPro data. The shares were sold on March 4, 2025, at a weighted average price of $51.52, resulting in a total transaction value of $63,369.

Following this transaction, Jacobson retains ownership of 19,118 shares in the company. The sale was executed in multiple trades with prices ranging from $51.50 to $51.54 per share. Jacobson has undertaken to provide detailed information regarding the number of shares sold at each price if requested by the SEC, the issuer, or a security holder of the issuer.

In other recent news, PTC Therapeutics reported its Q4 2024 earnings, revealing a slight miss in earnings per share (EPS) but meeting revenue expectations. The company posted an EPS of -$0.85, compared to the forecasted -$0.79, while revenue came in at $213 million, closely aligning with the anticipated $213.45 million. For the full year 2024, PTC Therapeutics achieved revenue of $877 million, surpassing its guidance. The company also maintains a strong cash position, bolstered by a $1 billion payment from Novartis (SIX:NOVN). Cantor Fitzgerald recently reiterated its Overweight rating on PTC Therapeutics with a price target of $113.00, despite adjusting its revenue estimates slightly lower based on the company’s 2025 guidance. The firm remains confident in PTC Therapeutics’ potential for growth and returns. These developments highlight PTC Therapeutics’ robust performance and strategic moves in the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.